Epitopes described in "Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis."

Article Authors:Berent J Prakken; Rodrigo Samodal; Tho D Le; Francesca Giannoni; Gisella Puga Yung; John Scavulli; Diane Amox; Sarah Roord; Isme de Kleer; Dustan Bonnin; Paola Lanza; Charles Berry; Margherita Massa; Rosario Billetta; Salvatore Albani
Article Title:Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis.
Reference Detail
Reference ID:1014545
Abstract:Modulation of epitope-specific immune responses would represent a major addition to available therapeutic options for many autoimmune diseases. The objective of this work was to induce immune deviation by mucosal peptide-specific immunotherapy in rheumatoid arthritis (RA) patients, and to dissect the related immunological mechanisms by using a technology for the detection of low-affinity class II-restricted peptide-specific T cells. A group of patients with early RA was treated for 6 months orally with dnaJP1, a peptide that induces proinflammatory T cell responses in naive RA patients. Immunological analysis at initial, intermediate and end treatment points showed an intriguing change from proinflammatory to regulatory T cell function. In fact, dnaJP1-induced T cell production of IL-4 and IL-10 increased significantly when initial and end treatment points were compared, whereas dnaJP1-induced T cell proliferation and production of IL-2, IFN-gamma, and tumor necrosis factor-alpha decreased significantly. The total number of dnaJP1-specific cells did not change over time, whereas expression of foxP3 by CD4+CD25(bright) cells increased, suggesting that the treatment affected regulatory T cell function. Thus, rather than clonal deletion, the observed change in immune reactivity to dnaJP1 was the outcome of treatment-induced emergence of T cells with a different functional phenotype. This study contributes to our knowledge of mechanisms and tools needed for antigen-specific immune modulation in humans, thus laying the foundation for exploitation of this approach for therapeutic purposes.
Affiliations:Departments of Medicine and Pediatrics, and IACOPO Institute for Translational Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0663, USA.
Reference Type:Literature
PubMed ID:15024101
Journal:Proc Natl Acad Sci U S A
Journal Volume:101
Article Pages:4228-33
Journal ISSN:0027-8424
Article Chemical List:gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@6afb5c0c;gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@1c584eb3;gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@6996d84e;gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@2e531f0a;gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@531ae148;gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@9bc6898;gov.nih.nlm.ncbi.www.jaxb.impl.NameOfSubstanceImpl@3076d826
Article MeSH List:Adjuvants, Immunologic(pharmacology); Arthritis, Rheumatoid(immunology; therapy); CD4-Positive T-Lymphocytes(drug effects; immunology); DNA-Binding Proteins(drug effects); Epitopes(immunology); Female; Forkhead Transcription Factors; Heat-Shock Proteins(pharmacology); Humans; Immunity, Mucosal(drug effects; immunology); Immunotherapy; Male; Middle Aged; Receptors, Interleukin-2(drug effects); T-Lymphocytes(drug effects; immunology)
Curation Last Updated:2015-04-28 17:28:05